Rossari Biotech Share Price
Sector: Chemical Manufacturing
690.15 -8.65 (-1.24%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
675.50
Today’s High
694.05
52 Week Low
568.05
52 Week High
966
690.20 -9.15 (-1.31%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
675.05
Today’s High
700
52 Week Low
569
52 Week High
972.70
Key Metrics
- Market Cap (In Cr) 3849.02
- Beta 1.17
- Div. Yield (%) 0.07
- P/B 3.69
- TTM P/E 31.57
- Peg Ratio 1.88
- Sector P/E 17.96
- Open Price 686
- Prev Close 698.8
Rossari Biotech Analysis
Price Analysis
-
1 Week2.69%
-
3 Months-4.18%
-
6 Month-8.52%
-
YTD-10.02%
-
1 Year-8.17%
Risk Meter
- 33% Low risk
- 33% Moderate risk
- 33% Balanced Risk
- 33% High risk
- 33% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 4
- 4
- 4
- 4
- Buy
- 0.00
- 0.00
- 0.00
- 0.00
- Hold
- 1
- 1
- 1
- 1
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 5
- 5
- 5
- 5
Rossari Biotech News
Stock to buy: Anand Rathi assigns ‘Buy’ call on Rossari Biotech, sees 26% upside
2 min read . 14 Jun 2024Rossari Biotech Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 1830.56
- Selling/ General/ Admin Expenses Total
- 282.44
- Depreciation/ Amortization
- 60.39
- Other Operating Expenses Total
- 11.52
- Total Operating Expense
- 1647.87
- Operating Income
- 182.69
- Net Income Before Taxes
- 177.62
- Net Income
- 130.69
- Diluted Normalized EPS
- 23.37
- Period
- 2024
- Total Assets
- 1572.15
- Total Liabilities
- 524.42
- Total Equity
- 1047.73
- Tangible Book Valueper Share Common Eq
- 142.07
- Period
- 2024
- Cashfrom Operating Activities
- 43.26
- Cashfrom Investing Activities
- -103.21
- Cashfrom Financing Activities
- 16.19
- Net Changein Cash
- -44.03
- Period
- 2023
- Total Revenue
- 1655.88
- Selling/ General/ Admin Expenses Total
- 241.16
- Depreciation/ Amortization
- 62.93
- Other Operating Expenses Total
- 20.39
- Total Operating Expense
- 1495.79
- Operating Income
- 160.09
- Net Income Before Taxes
- 144.22
- Net Income
- 107.26
- Diluted Normalized EPS
- 19.34
- Period
- 2023
- Total Assets
- 1367.57
- Total Liabilities
- 452.4
- Total Equity
- 915.17
- Tangible Book Valueper Share Common Eq
- 116.13
- Period
- 2023
- Cashfrom Operating Activities
- 151.56
- Cashfrom Investing Activities
- -180.89
- Cashfrom Financing Activities
- 60.86
- Net Changein Cash
- 31.72
- Period
- 2022
- Total Revenue
- 1482.97
- Selling/ General/ Admin Expenses Total
- 179.27
- Depreciation/ Amortization
- 48.06
- Other Operating Expenses Total
- 15.17
- Total Operating Expense
- 1342.66
- Operating Income
- 140.31
- Net Income Before Taxes
- 136.28
- Net Income
- 97.67
- Diluted Normalized EPS
- 16.99
- Period
- 2022
- Total Assets
- 1256.72
- Total Liabilities
- 451.56
- Total Equity
- 805.16
- Tangible Book Valueper Share Common Eq
- 98.93
- Period
- 2022
- Cashfrom Operating Activities
- 29.36
- Cashfrom Investing Activities
- -298.88
- Cashfrom Financing Activities
- 291.79
- Net Changein Cash
- 22.27
- Period
- 2021
- Total Revenue
- 709.35
- Selling/ General/ Admin Expenses Total
- 117.45
- Depreciation/ Amortization
- 22.83
- Other Operating Expenses Total
- 6.64
- Total Operating Expense
- 609.11
- Operating Income
- 100.24
- Net Income Before Taxes
- 106.84
- Net Income
- 80.22
- Diluted Normalized EPS
- 15.4
- Period
- 2021
- Total Assets
- 561.35
- Total Liabilities
- 152.58
- Total Equity
- 408.77
- Tangible Book Valueper Share Common Eq
- 76.14
- Period
- 2021
- Cashfrom Operating Activities
- 47.77
- Cashfrom Investing Activities
- -37.18
- Cashfrom Financing Activities
- -24.59
- Net Changein Cash
- -14
- Period
- 2020
- Total Revenue
- 600.09
- Selling/ General/ Admin Expenses Total
- 116.57
- Depreciation/ Amortization
- 16.85
- Other Operating Expenses Total
- 5.38
- Total Operating Expense
- 512.13
- Operating Income
- 87.96
- Net Income Before Taxes
- 87.84
- Net Income
- 65.25
- Diluted Normalized EPS
- 12.86
- Period
- 2020
- Total Assets
- 471.52
- Total Liabilities
- 184.84
- Total Equity
- 286.68
- Tangible Book Valueper Share Common Eq
- 55.55
- Period
- 2020
- Cashfrom Operating Activities
- 56.83
- Cashfrom Investing Activities
- -190.3
- Cashfrom Financing Activities
- 156.94
- Net Changein Cash
- 23.47
- Period
- 2019
- Total Revenue
- 516.22
- Selling/ General/ Admin Expenses Total
- 92.8
- Depreciation/ Amortization
- 12.26
- Other Operating Expenses Total
- 3.99
- Total Operating Expense
- 450.58
- Operating Income
- 65.64
- Net Income Before Taxes
- 63.39
- Net Income
- 45.68
- Diluted Normalized EPS
- 9
- Period
- 2019
- Total Assets
- 249.84
- Total Liabilities
- 126.03
- Total Equity
- 123.81
- Tangible Book Valueper Share Common Eq
- 23.22
- Period
- 2019
- Cashfrom Operating Activities
- 71.18
- Cashfrom Investing Activities
- -36.42
- Cashfrom Financing Activities
- -29.15
- Net Changein Cash
- 5.12
- Period
- 2018
- Total Revenue
- 299.06
- Selling/ General/ Admin Expenses Total
- 48.13
- Depreciation/ Amortization
- 5.17
- Other Operating Expenses Total
- 2.24
- Total Operating Expense
- 261.43
- Operating Income
- 37.63
- Net Income Before Taxes
- 37.47
- Net Income
- 25.4
- Diluted Normalized EPS
- 5.01
- Period
- 2018
- Total Assets
- 164.95
- Total Liabilities
- 77.87
- Total Equity
- 87.08
- Tangible Book Valueper Share Common Eq
- 17.15
- Period
- 2018
- Cashfrom Operating Activities
- 25.57
- Cashfrom Investing Activities
- -20.44
- Cashfrom Financing Activities
- -6.5
- Net Changein Cash
- -1.51
- Period
- 2024-12-31
- Total Revenue
- 512.73
- Selling/ General/ Admin Expenses Total
- 35.69
- Depreciation/ Amortization
- 18.32
- Other Operating Expenses Total
- 62.23
- Total Operating Expense
- 466.29
- Operating Income
- 46.45
- Net Income Before Taxes
- 42.38
- Net Income
- 31.7
- Diluted Normalized EPS
- 5.72
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 498.35
- Selling/ General/ Admin Expenses Total
- 32.56
- Depreciation/ Amortization
- 15.16
- Other Operating Expenses Total
- 59.14
- Total Operating Expense
- 447.57
- Operating Income
- 50.78
- Net Income Before Taxes
- 48.11
- Net Income
- 35.33
- Diluted Normalized EPS
- 6.38
- Period
- 2024-09-30
- Total Assets
- 1711.1
- Total Liabilities
- 593.4
- Total Equity
- 1117.7
- Tangible Book Valueper Share Common Eq
- 155.97
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 39.33
- Cashfrom Investing Activities
- -74.68
- Cashfrom Financing Activities
- 29.15
- Net Changein Cash
- -5.71
- Period
- 2024-06-30
- Total Revenue
- 489.65
- Selling/ General/ Admin Expenses Total
- 28.58
- Depreciation/ Amortization
- 15.37
- Other Operating Expenses Total
- 55.28
- Total Operating Expense
- 440.14
- Operating Income
- 49.51
- Net Income Before Taxes
- 46.99
- Net Income
- 34.9
- Diluted Normalized EPS
- 6.3
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 472.72
- Selling/ General/ Admin Expenses Total
- 25.04
- Depreciation/ Amortization
- 16.07
- Other Operating Expenses Total
- 44.63
- Total Operating Expense
- 424.02
- Operating Income
- 48.7
- Net Income Before Taxes
- 45.57
- Net Income
- 34.13
- Diluted Normalized EPS
- 6.17
- Period
- 2024-03-31
- Total Assets
- 1572.15
- Total Liabilities
- 524.42
- Total Equity
- 1047.73
- Tangible Book Valueper Share Common Eq
- 142.07
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 43.26
- Cashfrom Investing Activities
- -103.21
- Cashfrom Financing Activities
- 16.19
- Net Changein Cash
- -44.03
- Period
- 2023-12-31
- Total Revenue
- 463.77
- Selling/ General/ Admin Expenses Total
- 26.04
- Depreciation/ Amortization
- 15.09
- Other Operating Expenses Total
- 51.08
- Total Operating Expense
- 415.19
- Operating Income
- 48.58
- Net Income Before Taxes
- 47.78
- Net Income
- 34.39
- Diluted Normalized EPS
- 6.21
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 483.47
- Selling/ General/ Admin Expenses Total
- 27.53
- Depreciation/ Amortization
- 15.11
- Other Operating Expenses Total
- 49.61
- Total Operating Expense
- 435.02
- Operating Income
- 48.45
- Net Income Before Taxes
- 44.81
- Net Income
- 32.95
- Diluted Normalized EPS
- 5.95
- Period
- 2023-09-30
- Total Assets
- 1534.26
- Total Liabilities
- 555.99
- Total Equity
- 978.27
- Tangible Book Valueper Share Common Eq
- 127.64
- Period
- 2023-09-30
- Cashfrom Operating Activities
- -33.58
- Cashfrom Investing Activities
- -37.5
- Cashfrom Financing Activities
- 52.77
- Net Changein Cash
- -18.58
- Period
- 2023-06-30
- Total Revenue
- 410.61
- Selling/ General/ Admin Expenses Total
- 24.52
- Depreciation/ Amortization
- 14.11
- Other Operating Expenses Total
- 38.83
- Total Operating Expense
- 366.97
- Operating Income
- 43.63
- Net Income Before Taxes
- 39.46
- Net Income
- 29.22
- Diluted Normalized EPS
- 5.28
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 406.47
- Selling/ General/ Admin Expenses Total
- 26.78
- Depreciation/ Amortization
- 16.02
- Other Operating Expenses Total
- 38.84
- Total Operating Expense
- 367.9
- Operating Income
- 38.57
- Net Income Before Taxes
- 37.23
- Net Income
- 28.98
- Diluted Normalized EPS
- 5.24
- Period
- 2023-03-31
- Total Assets
- 1367.57
- Total Liabilities
- 452.4
- Total Equity
- 915.17
- Tangible Book Valueper Share Common Eq
- 116.43
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 152.39
- Cashfrom Investing Activities
- -180.89
- Cashfrom Financing Activities
- 60.86
- Net Changein Cash
- 32.36
- Period
- 2022-12-31
- Total Revenue
- 389.27
- Selling/ General/ Admin Expenses Total
- 24.18
- Depreciation/ Amortization
- 15.96
- Other Operating Expenses Total
- 38.53
- Total Operating Expense
- 351.06
- Operating Income
- 38.21
- Net Income Before Taxes
- 34.67
- Net Income
- 25.68
- Diluted Normalized EPS
- 4.63
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Rossari Biotech Technical
Moving Average
SMA
- 5 Day698.28
- 10 Day691.38
- 20 Day654.4
- 50 Day645.49
- 100 Day718.39
- 300 Day787.13
Rossari Biotech Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Bhagiradha Chemicals & Industri
- 304.95
- -5.45
- -1.76
- 448
- 168.7
- 3954.26
- Grauer & Weil (india)
- 86.61
- 0.17
- 0.2
- 120
- 72.16
- 3927
- Rossari Biotech
- 690.15
- -8.65
- -1.24
- 966
- 568.05
- 3849.02
- Nacl Industries
- 170.85
- -8.95
- -4.98
- 220.1
- 48.6
- 3407.42
- Tanfac Industries
- 3088
- -399.65
- -11.46
- 3970
- 1875.65
- 3080.28
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Bhagiradha Chemicals & Industri
- 191.89
- 7.75
- 12.14
- 6.75
- Grauer & Weil (india)
- 26.81
- 4.87
- 17.09
- 11.93
- Rossari Biotech
- 29.92
- 3.69
- 16.03
- 7.66
- Nacl Industries
- -
- 6.99
- 7.92
- 2.29
- Tanfac Industries
- 66.28
- 15.1
- 32.42
- 14.17
Rossari Biotech Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 25-Apr-25
- Audited Results & Final Dividend
- 21-Jan-25
- Quarterly Results
- 19-Oct-24
- Quarterly Results
- 20-Jul-24
- Quarterly Results
- 29-Apr-24
- Audited Results & Final Dividend
- 20-Jan-24
- Quarterly Results
- 21-Oct-23
- Quarterly Results
- 29-Jul-23
- Quarterly Results
- 29-Apr-23
- Audited Results & Final Dividend
- 04-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 11-Nov-24
- 21-Oct-24
- EGM
- 23-Aug-24
- 23-Jul-24
- AGM
- 08-Dec-23
- 09-Nov-23
- POM
- 31-May-23
- 05-May-23
- AGM
- 15-Jul-22
- 20-May-22
- AGM
- -
- 30-Jul-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 25-Apr-25
- -
- -
- 0.5
- 29-Apr-24
- -
- 16-Aug-24
- 0.5
- 02-May-23
- -
- 24-May-23
- 0.5
- 20-May-22
- -
- 07-Jul-22
- 0.5
- 14-May-21
- -
- 08-Sept-21
- 0.5


